Bridging the Gaps: iPSC-Based Models from CHIP to MDS to AML.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 28257709.
- Also identified by DOI 10.1016/j.stem.2017.02.011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Myeloid malignancies exist on a spectrum from asymptomatic clonal hematopoiesis to overt leukemia and exhibit substantial clonal heterogeneity. Both aspects are challenging to capture in experimental models. In two landmark studies in this issue of Cell Stem Cell, Kotini et al. (2017) and Chao et al. (2017) establish iPSC-based experimental platforms that recapitulate disease stages and clonal architecture.
Medical subject headings
- Hematopoiesis
- Myelodysplastic Syndromes